Production of quinone derived compounds in oleaginous yeast and fungi

1. An engineered Y. lipolytica strain comprising:

a combination of two or more quinonogenic modifications selected from the group consisting of:

a. increased expression or activity of a GGPP synthase polypeptide;

b. increased expression or activity of a truncated HMG CoA reductase polypeptide;

c. increased expression or activity of a 4-hydroxybenzoate polyprenyl transferase polypeptide;

d. increased expression or activity of a decaprenyl diphosphate synthase polypeptide;

e. increased expression or activity of a DAHP synthase polypeptide;

f. increased expression or activity of a chorismate lyase polypeptide;

g. increased expression or activity of a shikimate pathway polypeptide;

h. increased expression or activity of a chorismate mutase polypeptide;

i. increased expression or activity of a transketolase polypeptide;

j. increased expression or activity of an FPP synthase polypeptide;

k. increased expression or activity of an IPP isomerase polypeptide;

l. increased expression or activity of an HMG-CoA synthase polypeptide;

m. increased expression or activity of a mevalonate kinase polypeptide;

n. increased expression or activity of a phosphomevalonate kinase polypeptide;

o. increased expression or activity of a mevalonate pyrophosphate decarboxylate polypeptide;

p. increased expression or activity of a cytosolic malic enzyme polypeptide;

q. increased expression or activity of a malate dehydrogenase polypeptide;

r. increased expression or activity of an AMP deaminase polypeptide;

s. increased expression or activity of a glucose 6 phosphate dehydrogenase polypeptide;

t. increased expression or activity of a malate dehydrogenase homolog2 polypeptide;

v. increased expression or activity of a GND1-6-phosphogluconate dehydrogenase polypeptide;

w. increased expression or activity of a isocitrate dehydrogenase polypeptide;

x increased expression or activity of a IDH2-isocitrate dehydrogenase polypeptide;

y. increased expression or activity of a fructose 1,6 bisphosphatase polypeptide;

z. increased expression or activity of an Erg10-acetoacetyl CoA thiolase polypeptide;

aa. increased expression or activity of an ATP citrate lyase subunit 2 polypeptide;

bb. increased expression or activity of an ATP citrate lyase subunit 1 polypeptide;

cc. increased expression or activity of a chorsimate synthase polypeptide;

dd. decreased expression or activity of a squalene synthase polypeptide;

ee. decreased expression or activity of a prenyldiphosphate synthase polypeptide; and

ff. decreased expression or activity of a PHB polyprenyltransferase polypeptide;

wherein as a result of the combination of two or more quinonogenic modifications the engineered Y. lipolytica strain produces at least one quinone derived compound to at least about 1% of its dry cell weight; and

wherein the engineered strain can accumulate lipid to at least about 20% of its dry cell weight.

2. The engineered Y. lipolytica strain of claim 1 , wherein the combination of two or more quinonogenic modifications comprises:

a. increased expression or activity of a GGPP synthase polypeptide;

b. increased expression or activity of a 4-hydroxybenzoate polyprenyl transferase polypeptide;

c. increased expression or activity of a decaprenyl diphosphate synthase polypeptide;

d. increased expression or activity of a DAHP synthase polypeptide; and

e. increased expression or activity of a chorismate lyase polypeptide.

3. The engineered Y. lipolytica strain of claim 1 , further comprising at least one oleaginic modification.